Refine by
Tissue Testing Analysis Articles & Analysis
7 news found
CD BioSciences, a US-based biotechnology company focusing on the development of imaging technologies, is excited to announce the launch of its new Immune System Tissue Microarrays for the scientific community to study the complex interactions of the immune system in various tissues. These innovative products offer researchers a powerful tool to unravel the complexities of the immune system and ...
CD BioSciences, a US-based biotechnology company focusing on the development of imaging technology, announced the launch of its new 3D Tissue Imaging Services to researchers with comprehensive solutions for 3D imaging of tissues, including 3D Immunolabeling, Tissue Removal, 3D Imaging, and Quantitative Image Analysis. Traditional tissue analysis typically uses frozen or paraffin-embedded ...
The Microplate Reader Company – and InvivoSciences, Inc. – a leader in stem cell tissue engineering providing a novel solution in first-in-class drug discovery – announced today a strategic collaboration to market the time-dependent fluorescent assessment of engineered 3D heart tissues using advanced microplate reader technologies. Employing an automated system, 3D heart ...
Its PROTAC in vivo evaluation services encompass general studies of toxicology and in vivo pharmacokinetics, tests of allergy and in vitro hemolysis, as well as immunotoxicology analysis. ...
RSIP Vision, an experienced leader in driving innovation for medical imaging through advanced AI and computer vision solutions, today announces a new tool for Total Shoulder Arthroplasty (TSA) planning. This tool performs segmentation of the shoulder bones from shoulder MRI scan, which is usually performed in shoulder healthcare. The segmentation output undergoes super-resolution enhancement to ...
Hard-to-detect cancers like glioblastoma can have survival rates in the single-digit percentages and require elaborate techniques to detect, treat, and monitor. Reveal Surgical is working on changing that reality through its new, AI-based Sentry technology, which leverages a combination of AI and Raman spectroscopy to provide real-time tissue diagnostics during surgery for otherwise-invisible ...
SAN DIEGO, November 22, 2019 – Avelas Biosciences, Inc., a clinical-stage oncology company developing AVB-620 for real-time cancer detection is pleased to announced the addition of Susan Stimson as a Director of the company. “Susan brings an exceptional background and skillset to the Avelas Board. She has had incredible success throughout her career and her knowledge and experiences ...